Form 4: Cartesian Therapeutics Director Acquires Equity

Cartesian Therapeutics Director and 10% owner Murat Kalayoglu acquired 2,600 Restricted Stock Units and 7,800 stock options on January 2, 2026.

Summary

• Murat Kalayoglu, a Director and 10% Owner of Cartesian Therapeutics, Inc. (RNAC), reported transactions on January 2, 2026.
• Kalayoglu acquired 2,600 shares of Common Stock in the form of Restricted Stock Units (RSUs) at a price of $0 per share.
• These 2,600 RSUs are scheduled to vest in full on January 2, 2027.
• Kalayoglu also acquired 7,800 Stock Options (Right to Buy) at a price of $0, with an exercise price of $6.76 per share.
• The acquired stock options become exercisable on January 2, 2027, and have an expiration date of January 1, 2036.
• Following these transactions, Kalayoglu directly beneficially owns 511,577 shares of Common Stock and 7,800 Stock Options.
• Additionally, 4,555,260 shares of Common Stock are indirectly beneficially owned by Kalayoglu through a trust for the benefit of his spouse and children.

Sentiment

Score: 7

Explanation: The acquisition of additional equity by a director and 10% owner, particularly through grants of RSUs and stock options, generally indicates a positive sentiment and confidence in the company's future performance.

Positives

• A Director and 10% Owner acquiring additional equity (RSUs and stock options) can signal confidence in the company's future prospects.
• The acquisition of RSUs and stock options at a $0 price indicates a grant, which is a common form of executive compensation aligning management interests with shareholders.

Future Outlook

This filing does not contain any forward-looking statements or guidance from the company regarding its future performance or strategic direction.

Industry Context

This Form 4 filing reports an insider transaction, which is specific to the individual's equity holdings and does not directly provide information on broader industry trends or competitive landscape. However, insider buying can be interpreted by the market as a signal of management's confidence in the company's future within its industry.

Related Party Transactions

• 4,555,260 shares of Common Stock are indirectly beneficially owned through a trust for the benefit of the reporting person's spouse and children, with the spouse serving as a trustee.

Stakeholder Impact

• Shareholders may view the insider's acquisition of additional equity as a positive signal, potentially increasing confidence in the company's leadership and future prospects.
• The grants of RSUs and stock options align the interests of the director with those of other shareholders, as the value of these holdings is tied to the company's stock performance.

Next Steps

• The 2,600 Restricted Stock Units are expected to vest on January 2, 2027.
• The 7,800 Stock Options will become exercisable on January 2, 2027, and can be exercised until their expiration on January 1, 2036.

Key Dates

Keywords

Cartesian Therapeutics, RNAC, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Director, 10% Owner, Equity Acquisition